TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Patients with Recurrent or Persistent Ovarian Epithelial Cancer, FTC, and PPC
Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Drug treatment options for patients with recurrent disease are subdivided as follows:
Platinum-sensitive recurrence: For patients whose disease recurs more than 6 months after cessation of the induction therapy, re-treatment with a platinum or platinum-containing combination, such as carboplatin, should be considered (see Table 8).
Source links and citations
Platinum-refractory or platinum-resistant recurrence: For patients who progress before cessation of induction therapy (platinum refractory) or within 6 months after cessation of induction therapy (platinum resistant), platinum therapy is generally not useful as part of the treatment plan. Clinical trials should be considered.
Source links and citations
Other agents that have shown activity in phase II trials are listed in Table 10 and may also be used alone or in combination with other drugs, but such treatments are best done in prospective trials.
Source links and citations
Cytoreduction may be used;[4] this intervention has been studied in the setting of randomized clinical trials (e.g., GOG-0213 [NCT00565851], DESKTOP III [NCT01166737], and SOC 1 [NCT01611766]). The SOC 1 trial was published with immature survival data.[6] Eligibility criteria differed between each of the trials. Only 67% of patients achieved complete gross resections in the GOG-0213 trial,[7] compared with 77% of patients in the SOC 1 trial and 75% of patients in the DESKTOP III trial.[8] The Dutch SOCcer trial was closed prematurely in 2015 because only 27 of 230 planned patients (12%) were accrued in 5 years.[9,10] In order for the GOG trial to study the role of surgery, the target enrollment was 485 patients which took almost 10 years to achieve.
The role of radiation therapy in patients with recurrent ovarian cancer has not been defined.
Continue within this section
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice